NCT01943084 - A Trial to Investigate the Bioequivalence of Norditropin® (Somatropin) Versus Genotropin® (Somatropin) in Healthy Adult Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions

Growth DisorderHealthy

Interventions

DRUG

Norditropin® FlexPro® pen

Administered as a single subcutaneous (s.c., under the skin) dose (4.0 mg) on 2 separate dosing visits (treatment periods). The 2 treatment periods will be separated by a 7-day washout period.

DRUG

Genotropin Pen®

Administered as a single subcutaneous dose (4.0 mg) on 2 separate dosing visits (treatment periods). The 2 treatment periods will be separated by a 7-day washout period.

Trial Locations (1)

66212

Novo Nordisk Clinical Trial Call Center, Overland Park